Eric Luria Goldwaser, D.O., Ph.D

Justin Rossi, M.D., Ph.D. is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medicine. Dr. Rossi received his undergraduate degree from Harvard University and his combined medical degree - doctoral degree in Neuroscience from the University of Florida College of Medicine. He is the author of over two dozen peer-reviewed scientific articles in the areas of psychiatry, neurology, and neuromodulation. He completed his general psychiatry residency at the University of California San Francisco and his child and adolescent psychiatry training at the NYP-Columbia-Cornell Child and Adolescent Psychiatry Residency Training Program. As faculty, Dr. Rossi continues his research in neuromodulation in the Transcranial Magnetic Stimulation Program. Dr. Rossi participates in the Weill Cornell Medicine faculty practice, where he sees children, adolescents, and adults. Dr. Rossi's clinical interests include ADHD, anxiety disorders, and depression.

Robert Michels, M.D., is the Walsh McDermott University Professor of Medicine, and University Professor of Psychiatry at Weill Cornell Medicine, where he was formerly Chair of the Department of Psychiatry and Dean and Provost for Medical Affairs.

Dr. Kaner is Associate Attending Physician at the NewYork-Presbyterian Weill Cornell Medical Center and Associate Professor of Clinical Medicine and Genetic Medicine at Weill Cornell Medicine. Dr. Kaner was the Principal Investigator of the Weill-Cornell Medicine site of the NIH-sponsored Idiopathic Pulmonary Fibrosis (IPF) Clinical Research Network for which he chaired the Adjudication Committee. He has extensive experience in the phenotyping of subjects with lung disease and their enrollment in research studies. He leads a monthly multidisciplinary ILD conference with Dr. William Travis (MSKCC) and Dr. Chen Zhang (WCM) for the past 15 years. He is the director of the New York Presbyterian Hospital – Weill Cornell Medicine Pulmonary Fibrosis Foundation Clinical Center of Excellence. He participates in clinical trials evaluating various pharmacologic interventions in IPF and other ILDs, sponsored by both NIH and pharma. He leads an ILD biobank, which enhances future translational research opportunities. He leads an observational study to determine the incidence and natural history of ILD following COVID-19 acute respiratory failure.Dr. Kaner chairs the bronchoscopy sub-study committee of the NHLBI SPIROMICS and SOURCE research networks, which uses RNA-sequencing to evaluate gene expression changes in lung cells associated with smoking and COPD endotypes. He is analyzing the effects of doxycycline on BAL matrix metalloproteinase (MMP) inhibition in HIV-positive individuals with early emphysema, based on his previous translational work. He is also participating in pharmacologic intervention studies in COPD and emphysema sponsored by the ALA, DOD and NIH, including leadership (with Dr. Marshall Glesby) of a Phase II multicenter trial of doxycycline to slow emphysema progression in PLWH. He is the Associate Director of the T32 training program and Associate Fellowship Program Director.